Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 14/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.54 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760903 | 0.90 | RAB9A (0.64) | NOTUMTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL11401928 | 0.82 | DPP8 (0.53) | NAMPTTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL22664279 | 0.80 | NAMPT (0.55) | NAMPT | |
| SCHEMBL20612064 | 0.80 | DPP8 (0.54) | NAMPTTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL11317727 | 0.80 | MAPT (0.48) | NAMPTNPC1MAPTRAB9AKMT2A | |
| SCHEMBL13884527 | 0.79 | NOTUM (0.58) | NOTUMTAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL7602212 | 0.79 | NOTUM (0.61) | NOTUMNAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13884531 | 0.77 | USP2 (0.57) | NOTUMNPC1MAPTRAB9AKMT2A | |
| SCHEMBL18205171 | 0.75 | DPP8 (0.53) | NOTUMNAMPTTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL22332044 | 0.75 | RAB9A (0.55) | NOTUMTAS1R3TAS1R1TAS1R2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611271-B2 | C20′ urea derivatives of vinca alkaloids | SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611271-B2 | C20′ urea derivatives of vinca alkaloids | SCRIPPS RESEARCH INSTITUTE (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150291610-A1 | C20' Urea Derivatives of Vinca Alkaloids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291610-A1 | C20' Urea Derivatives of Vinca Alkaloids | UTP18, SNRPA1, SNRPA | NOTUM 2370/4885NAMPT 925/4885TAS1R3 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.